Modeling study demonstrates reduced exacerbation rates, mortality, and costs with single-inhaler triple therapy in COPD, indicating major clinical and economic gains from guideline adherence.
The model shows that increased SITT use in France, in line with recent recommendations, could be associated with a reduction in exacerbation rates, mortality, and costs in patients with COPD.
No takes yet. Share an insight, caveat, or question.
Deslée et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: